Tempus and Bayer have collaborated on a program to facilitate testing for US-based patients with metastatic colorectal cancer (mCRC) with high Microsatellite Instability (MSI-H) status and patients with radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Bayer will cover the cost of the multi-gene panel (Tempus xT test), regardless of the results and treatment decision, as long as the patient meets the program eligibility criteria. The test results provide information on a broad range of genomic alterations, including the Neurotrophic Tropomyosin Receptor Kinase (NTRK) gene fusion, that aid physicians in making treatment decisions appropriate for patients with advanced and metastatic cancer.
Tempus’ xT solid tumor assay covers 648 genes through DNA sequencing and whole transcriptome RNA sequencing with CAP/CLIA validated fusion detection. The panel identifies oncogenic drivers including BRAF, KRAS, RET and NTRK gene fusions.
OUR GENOMIC SEQUENCING
We’ve built a state-of-the-art, CAP-accredited and CLIA-certified lab. Our highly robotic laboratory is optimized for high-throughput clinical next-generation sequencing with a current capacity of over 100,000 patients annually.
FEATURES
648 gene DNA panel sequenced at average 500x depth of coverage
Sequencing of FFPE tumor tissue and normal matched (through blood or saliva) specimens; includes reporting of 46 incidental germline findings
MSI Status and Tumor Mutational Burden (TMB)
Full transcriptome by RNA sequencing (including CAP/CLIA-validated identification of relevant fusions)
SPECIMEN TYPES
FFPE tissue slides or blocks
Normal matched (blood or saliva)
FEATURES
648 gene panel sequenced at average 500x depth of coverage
MSI Status and Tumor Mutational Burden (TMB)
Full transcriptome by RNA sequencing (including CAP/CLIA-validated detection of relevant fusions)
SPECIMEN TYPES
FFPE tissue slides or blocks
Recommended when unable to obtain normal matched specimen or if the normal matched specimen cannot be successfully sequenced
Note: All additional tests ordered beyond xT will be billed to insurance.
OUR PROCESS